Bubble or no bubble, this is the best stock for AI exposure: analyst
RedHill Biopharma Ltd. (NASDAQ:RDHL) announced Wednesday that it has filed a prospectus supplement to raise the maximum aggregate offering amount of its American Depositary Shares (ADSs) that may be issued and sold under its existing At The Market Offering Agreement. Each ADS represents 10,000 ordinary shares of the company.
The At The Market Offering Agreement was originally entered into with H.C. Wainwright & Co., LLC on February 3, 2025. The increase in the offering amount allows RedHill Biopharma to potentially sell additional ADSs from time to time, subject to market conditions and other factors.
The company is incorporated in Israel and is focused on pharmaceutical preparations. The filing was signed by Chief Executive Officer Dror Ben-Asher.
This information is based on a statement in a press release filed with the Securities and Exchange Commission.
In other recent news, Macy’s announced the opening of its largest customer fulfillment center in China Grove, North Carolina. The 2.5 million square foot facility features advanced automation technology and will initially support Macy’s brand fulfillment and store replenishment. Macy’s also declared a quarterly dividend of 18.24 cents per share, payable on January 2, 2026, to shareholders of record as of December 15, 2025. BTIG initiated coverage on Macy’s with a Neutral rating, acknowledging the retailer’s strategic progress while expressing caution due to recent stock price appreciation.
Additionally, Navient’s affiliate has announced its plans for the upcoming auctions of SLM Student Loan Trust 2006-7 notes. The affiliate intends to submit a Hold Order for all Class A-6B Notes it currently holds, as stated in a recent SEC filing. VivoPower International has scheduled its Annual General Meeting for December 15, 2025, in London. Shareholders will vote on resolutions including the approval of the directors’ remuneration report and the re-appointment of auditors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.